These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29147818)

  • 1. Inhalation Biopharmaceutics: Progress Towards Comprehending the Fate of Inhaled Medicines.
    Ehrhardt C
    Pharm Res; 2017 Dec; 34(12):2451-2453. PubMed ID: 29147818
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of pulmonary diseases on the fate of inhaled medicines--a review.
    Wang YB; Watts AB; Peters JI; Williams RO
    Int J Pharm; 2014 Jan; 461(1-2):112-28. PubMed ID: 24291124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaling medicines: delivering drugs to the body through the lungs.
    Patton JS; Byron PR
    Nat Rev Drug Discov; 2007 Jan; 6(1):67-74. PubMed ID: 17195033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary absorption - estimation of effective pulmonary permeability and tissue retention of ten drugs using an ex vivo rat model and computational analysis.
    Eriksson J; Sjögren E; Thörn H; Rubin K; Bäckman P; Lennernäs H
    Eur J Pharm Biopharm; 2018 Mar; 124():1-12. PubMed ID: 29191716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals.
    Nahar K; Gupta N; Gauvin R; Absar S; Patel B; Gupta V; Khademhosseini A; Ahsan F
    Eur J Pharm Sci; 2013 Aug; 49(5):805-18. PubMed ID: 23797056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug transporters in the lung--do they play a role in the biopharmaceutics of inhaled drugs?
    Bosquillon C
    J Pharm Sci; 2010 May; 99(5):2240-55. PubMed ID: 19950388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects.
    Rogueda PG; Traini D
    Expert Opin Drug Deliv; 2007 Nov; 4(6):595-606. PubMed ID: 17970663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery.
    Sakagami M
    Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1030-60. PubMed ID: 17010473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. iBCS: 3. A Biopharmaceutics Classification System for Orally Inhaled Drug Products.
    Hastedt JE; Bäckman P; Cabal A; Clark A; Ehrhardt C; Forbes B; Hickey AJ; Hochhaus G; Jiang W; Kassinos S; Kuehl PJ; Prime D; Son YJ; Teague S; Tehler U; Wylie J
    Mol Pharm; 2024 Jan; 21(1):164-172. PubMed ID: 38059771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary drug delivery: medicines for inhalation.
    Henning A; Hein S; Schneider M; Bur M; Lehr CM
    Handb Exp Pharmacol; 2010; (197):171-92. PubMed ID: 20217530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties.
    Tolman JA; Williams RO
    Drug Dev Ind Pharm; 2010 Jan; 36(1):1-30. PubMed ID: 19640248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current approaches to the discovery of novel inhaled medicines.
    Strong P; Ito K; Murray J; Rapeport G
    Drug Discov Today; 2018 Oct; 23(10):1705-1717. PubMed ID: 29775668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selected Engineering and Physicochemical Aspects of Systemic Drug Delivery by Inhalation.
    Sosnowski TR
    Curr Pharm Des; 2016; 22(17):2453-62. PubMed ID: 26818874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimisation of DMPK by the inhaled route: challenges and approaches.
    Cooper AE; Ferguson D; Grime K
    Curr Drug Metab; 2012 May; 13(4):457-73. PubMed ID: 22299825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Where a pill won't reach.
    Langer R
    Sci Am; 2003 Apr; 288(4):50-7. PubMed ID: 12661315
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs.
    Bäckman P; Arora S; Couet W; Forbes B; de Kruijf W; Paudel A
    Eur J Pharm Sci; 2018 Feb; 113():41-52. PubMed ID: 29079338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into Inhalation Drug Disposition: The Roles of Pulmonary Drug-Metabolizing Enzymes and Transporters.
    Dong L; Zhuang X
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary drug absorption and systemic exposure in human: Predictions using physiologically based biopharmaceutics modeling.
    Eriksson J; Thörn H; Lennernäs H; Sjögren E
    Eur J Pharm Biopharm; 2020 Nov; 156():191-202. PubMed ID: 32941997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights on animal models to investigate inhalation therapy: Relevance for biotherapeutics.
    Guillon A; Sécher T; Dailey LA; Vecellio L; de Monte M; Si-Tahar M; Diot P; Page CP; Heuzé-Vourc'h N
    Int J Pharm; 2018 Jan; 536(1):116-126. PubMed ID: 29180257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Affecting Drug Exposure after Inhalation.
    Nováková A; Šíma M; Slanař O
    Prague Med Rep; 2022; 123(3):129-139. PubMed ID: 36107443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.